Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06422715
Active, not recruiting Observational

PTLD: Multicentric Retrospective Study

NCT06422715 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Started
2024-10-30
Last updated
2025-12-02

Condition(s) studied

PTLD

Study summary

This is a multicentric observational retrospective cohort study of patients with histological diagnosis of PTLD.

The aim of the study is to analyze the clinical features and survival of patients who received a PTLD diagnosis with the target to assess a survival outcome, to obtain an epidemiologic and clinical characterization of the subpopulations affected by PTLD, to recognize unfavorable properties, to report the current treatment strategies, to provide rationale for the design of a prospective registry in order to develop future novel treatments.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * histological diagnosis of PTLD obtained from a biopsy sample (availability of stocked biopsy sample is requested but not mandatory); * age over 18 years at time of diagnosis of PTLD; * previously subjected to allogeneic transplantation (both SOT and HSCT); * diagnosis of PTLD obtained in 10 years' time frame (from 01/01/2011 to 31/12/2021); * free and voluntary written informed consent (included unreachable subjects according to Art. 36 UE Regulation 2016/679 and to the current Italian Privacy Regulation). Exclusion Criteria: * Patients not meeting the above-mentioned inclusion criteria.

Primary outcome measure(s)

Trial sites (21)

FacilityCityRegionStatus
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Ematologia Milan MI
Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati Aviano Italy
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia Bergamo Italy
A.O. UNIVERSITARIA POLICLINICO S.ORSOLA-MALPIGHI DI BOLOGNA - Istituto di Ematologia "Seragnoli" Bologna Italy
A.O. Spedali Civili di Brescia - Ematologia Brescia Italy
Ospedale Businco - Divisione di Ematologia Cagliari Italy
A.O. S. Croce e Carle - S.C. di Ematologia e Trapianto di Midollo Osseo Cuneo Italy
A.O. UNIVERSITARIA CAREGGI DI FIRENZE - Unità funzionale di Ematologia Florence Italy
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia Miano Italy
Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia Milan Italy
AOU Maggiore della Caritа di Novara - SCDU Ematologia Novara Italy
IRCCS ISTITUTO ONCOLOGICO VENETO (IOV) - Oncologia 1 Padova Italy
IRCCS Policlinico San Matteo - Divisione di Ematologia Pavia Italy
Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare Roma Italy
Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia Roma Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica S. Cuore - Ematologia Roma Italy
AOU Senese - U.O.C. Ematologia Siena Italy
A.O. UNIVERSITARIA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - SC Ematologia Torino Italy
A.O. Città della Salute e della Scienza - Ematologia Universitaria Torino Italy
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica Udine Italy
ULSS 8 Berica - Ospedale S. Bortolo - Ematologia Vicenza Italy

More Fondazione Italiana Linfomi - ETS trials in Italy

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma Recruiting
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. Active, not recruiting
Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice Starting soon
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. Active, not recruiting
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06422715 on ClinicalTrials.gov ↗ ← All trials in Italy